Driving Progress in the Biosimilar Marketplace
Oct 12, 2017
In 2010, the Biologics Price Competition and Innovation Act (BPCIA) established an abbreviated approval pathway for “follow-on” biologics or biosimilar products. Since then, the market for biosimilars has been mired in uncertainty.
The BPCIA contains language known as the “patent dance,” which has tied up the release of several biosimilar drugs. The patent dance instructs the biosimilar manufacturer to share information about its manufacturing process with the reference manufacturer. It also required the biosimilar manufacturer to inform the reference manufacturer 180 days before marketing its product. Since the BPCIA, only a handful of biosimilar drugs have been approved.
In the June 2017 case Sandoz Inc. v. Amgen Inc., the U.S. Supreme Court reviewed the patent dance and ruled its provisions are not mandatory for biosimilar manufacturers. While it is still difficult to predict how the biosimilar market will fare, this opinion could accelerate the release of biosimilars into the marketplace.
Medication Access & Guidance: How EnvoyHealth Can Help
Especially given the possibility of faster speed to market, biosimilar manufacturers need strong services support to help patients and providers choose their drugs. EnvoyHealth works with manufacturers to streamline access for patients and providers. Our services make it easier for providers to learn about and understand biosimilar products—and for patients to adhere to them.
EnvoyHealth’s team includes patient access and reimbursement specialists, customer care specialists, pharmacists, nurses, and sales professionals. Together, these highly trained professionals provide the highest-quality multichannel services to support biosimilar medications, including:
- Reimbursement hub support
- Patient education and support
- Medical and product information
- Product complaint and adverse-event intake
- Customer care
- Technical support
- Inside sales, including teledetailing
EnvoyHealth’s suite of services helps biosimilar manufacturers offer a complete patient access and clinical care solution. Our full reimbursement hub eliminate barriers, helping patients, caregivers, and providers navigate the complex reimbursement process. Whether the need is for prior authorization or insurance appeal, these knowledgeable professionals can assist you. Our professionals have provided medical information and support to millions of patients and providers over the past 20 years. From patient education to recognizing and documenting adverse events, we have experts on hand 24/7.
PharmaOpioid Dependence: How Hub Services Can Help
Nov 16, 2017
PharmaPharmaceutical Manufacturing Predictions for 2018
Nov 2, 2017
PharmaSpeeding Up Clinical Trials With Remote Monitoring Support
Sep 28, 2017